noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

ImmuCell Corporation

2025 Form 10-K (proofs 0000811641 118730 ALL DOCS clean pn120)
Peakequity Partners Management Co LLC

PeakEquity Partners Successfully Exits G5
Peakequity Partners Management Co LLC

Thoma Bravo Completes Strategic Investment in PeakEquity Portfolio[...]

Healthcare

Pappas Capital LLC

02/23/2016 | Press release | Archived content

CoLucid Pharmaceuticals Announces Confirmatory Support for Non-va...

News | 02. 23. 2016

CoLucid Pharmaceuticals

CAMBRIDGE, Mass., Feb. 23, 2016 - CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD), a Phase 3 clinical-stage biopharmaceutical company that is developing its lead product candidate, lasmiditan, for the acute treatment of migraine headaches, announced today the completion of a preclinical in vivo study examining the effect of lasmiditan on coronary and carotid artery diameters. This study confirms the lack of effect of lasmiditan on coronary artery and carotid artery vasoconstriction; the data are expected to be used in support of potential future regulatory filings.

Pappas Capital LLC published this content on February 23, 2016, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 22, 2026 at 10:00 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]

Back

View original format